外部サイト へ移動します。

この先のサイトでは当サイトのプライバシーポリシー、ご利用規則は適用されません。リンク先のプライバシーポリシー等をご確認ください。

アムジェンとキャンサースキャン
大阪市における骨粗しょう症の二次骨折予防を目的とした
官民連携による骨粗しょう症疾患啓発事業協定を新たに締結

後期高齢者医療制度の被保険者にも対象を拡大した事業を実施

アムジェン株式会社(本社:東京、以下「アムジェン」)と株式会社キャンサースキャン(本社:東京、代表取締役:福吉 潤、以下「キャンサースキャン」)は、大阪市と「官民連携による骨粗しょう症疾患啓発事業協定(疾患啓発コモンズ)」(以下、本事業)を新たに締結したことを発表しました。本事業では、2021年3月から10月までに実施した前事業の結果を踏まえ、国民健康保険の被保険者に加え、後期高齢者医療制度の被保険者も事業の対象として実施します。また受診勧奨方法についても改善を加えて実施する予定にしています。

前事業では、40~74歳の大阪市の国民健康保険被保険者のうち、過去に脆弱性骨折の既往があるにもかかわらず骨粗しょう症の治療歴がない市民520名を対象に、「骨粗しょう症」に関する受診を促す勧奨通知を実施しました。効果検証の結果、骨粗しょう症診療の受診率が前年比1.8倍になりました1

大阪市ウェブサイト:
大阪市における二次骨折予防を目的とした骨粗しょう症疾患啓発事業報告書
https://www.city.osaka.lg.jp/kenko/page/0000570308.html

一方で前事業では、骨粗しょう症による脆弱性骨折リスクが高く、適切な診断、治療がより必要な75歳以上の年齢層が含まれていませんでした。そのため本事業では、国民健康保険の被保険者に加え、後期高齢者医療制度の被保険者も対象に加え啓発事業を行う計画です。

本事業の実施にあたって、大阪市とキャンサースキャン、アムジェンの三者は、高齢化に伴う課題のひとつである骨折予防にフォーカスしています。介護予防や健康寿命の延伸を目指して、骨粗しょう症の検査や治療が勧められる方の受診行動を促し、適切な医療へつなげられるよう取り組んで参ります。

脆弱性骨折について
世界的に、50歳以上の女性3人に1人、男性5人に1人が骨粗しょう症による脆弱性骨折を起こすとされており、高齢化に伴いこの数はさらに増加する見込みです2。また、骨粗しょう症による脊椎や大腿骨近位部骨折は、日々の活動に著しく影響し患者さんのQOLを低下させ、救急病棟を含む通院を増やし、治療費の増加につながります3。大腿骨近位部骨折患者さんのその後の生存率は、一般人口より低い推移を示します4。こうした状況にもかかわらず、日本の骨粗しょう症患者さんのうち治療を受けている割合は、わずか20%程度(推定)に過ぎません2,5。また、脆弱性骨折は介護や寝たきりの要因でもあります。官公庁統計を基にした試算では、骨折・転倒を要因とする介護サービス負担は2018年には1.9-2.8兆円、その中でも家族による介護負担は0.8-1.7兆円と、最も大きな要素となっていることが報告されています6

アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については www.amgen.co.jp をご覧になるか、https://www.facebook.com/amgenjapan をフォローしてください。

株式会社キャンサースキャンについて
キャンサースキャンは、「人と社会を健康に」というミッションの達成に向け、データサイエンスとマーケティング、行動経済学、公衆衛生の専門知識を掛け合わせ、特定健診の受診勧奨や生活習慣病の重症化予防を目的とした受領勧奨、がん検診の受診勧奨、予防医療にかんする新たな事業開発等、日本の予防医療の推進を支援する各種事業を展開しております。
累計700以上の市町村での各種保健事業の実施支援を通じて、コミュニケーションを変え、社会の仕組みを変えながら、健康になるための行動変容にフリクションがない世界を目指しています。
ウェブサイト:https://cancerscan.jp/

Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

注意事項(アムジェン株式会社)
このニュースリリースに含まれている医薬品(開発中のものを含む)に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。

###

この件に関するお問い合わせ先

アムジェン株式会社(東京)
コーポレート・アフェアーズ
TEL 03-4563-8610

株式会社キャンサースキャン
北村早紀
TEL 03-6420-3390
Mail info@cancerscan.jp

References

  1. 大阪市における二次骨折予防を目的とした骨粗しょう症疾患啓発事業報告書
  2. International Osteoporosis Foundation. Facts and statistics: Epidemiology of osteoporosis and fragility fractures
  3. Fujiwara, S, et al. J Bone Miner Metab. 2019; 37(2): 307-318.
  4. 折茂肇: 日本臨牀. 2004; 62(増刊2):1-6.
  5. Tsuboi, M., Hasegawa, Y., Suzuki, S., Wingstrand, H., Thorngren, K.-G. (2007). Mortality and mobility after hip fracture in Japan. J Bone Joint Surg [Br], 89-B(4), 461-466.
  6. ミリマン・インク 日本における骨折による介護負担とその推移‐官庁統計を用いた分析